Formerly doing business as Algenix Inc, in 2002, the firm was renamed as BioViRx with facilities also in Taiwan. BIOVIRx, Inc. is a privately held biopharmaceutical company formed to acquire and distribute pharmaceutical and health products in the U.S. and global markets. Its initial product, RotaShield®, was acquired under an exclusive, worldwide license from the U.S. National Institutes of Health ("NIH"). RotaShield® is an oral pediatric vaccine intended for use in preventing rotavirus infection.. Algenix Inc's lead product in development had been the LIVERX 2000 SYSTEM, is an external liver support system that incorporates porcine liver cells. It was designed to treat acute and chronic liver failure by temporarily providing essential liver function to those patients hospitalized with liver failure. The BioVirx product RotaShield® is an oral pediatric vaccine for use in preventing rotavirus infection and was previously marketed by Wyeth Pharmaceuticals, Inc. The firm's exclusive RotaShield® license provides a unique opportunity to reintroduce a proven vaccine to a large worldwide market in a significantly abbreviated time frame. The effort is to launch RotaShield® in the U.S. and international markets by 2
